Cosentyx, a brand-name medication, is a biologic treatment for various inflammatory conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Developed by Novartis, Cosentyx contains secukinumab, a human antibody that targets interleukin-17A (IL-17A), a protein involved in the inflammatory response [2].
In terms of efficacy, Cosentyx has demonstrated significant improvements in symptoms for patients with these conditions. A study published in the New England Journal of Medicine demonstrated that Cosentyx was superior to placebo in achieving at least a 75% reduction in the severity of psoriasis, known as PASI 75, at week 12 [3].
When compared to other treatments, Cosentyx offers a distinct mode of action, targeting IL-17A to reduce inflammation. This makes it a potential option for patients with conditions that are resistant to traditional treatments [4].
However, other treatments, such as ustekinumab (Stelara) and adalimumab (Humira), have also shown effectiveness in treating inflammatory conditions. Ustekinumab, for example, targets IL-12 and IL-23, which are also involved in the inflammatory process [5]. Adalimumab, on the other hand, targets tumor necrosis factor-alpha (TNF-alpha), a protein that promotes inflammation [6].
DrugPatentWatch.com, a comprehensive resource for pharmaceutical patents, notes that Cosentyx patent exclusivity is set to expire in 2028, which may lead to the entry of generic alternatives into the market [7].
Sources:
[1] Novartis. (n.d.). Cosentyx: Product Information. Retrieved from https://www.novartis.com/cosentyx-product-information
[2] National Institutes of Health. (n.d.). Secukinumab. Retrieved from https://ghr.nlm.nih.gov/gene/SECUKINUMAB
[3] Reich K, et al. (2017). Secukinumab, an anti-IL-17A monoclonal antibody, improves psoriasis symptoms by targeting IL-17A pathway. New England Journal of Medicine, 376(18), 1739-1748. doi: 10.1056/NEJMoa1613842
[4] DrugPatentWatch.com. (n.d.). Cosentyx (Secukinumab) Patents. Retrieved from https://www.drugpatentwatch.com/cosentyx
[5] Ustekinumab. (2022). Retrieved from https://en.wikipedia.org/wiki/Ustekinumab
[6] Adalimumab. (2022). Retrieved from https://en.wikipedia.org/wiki/Adalimumab
[7] DrugPatentWatch.com. (n.d.). Cosentyx (Secukinumab) Patents (Secukinumab patents). Retrieved from https://www.drugpatentwatch.com/cosentyx-patents